FDA Denial Of Saw Palmetto Health Claim For BPH Prompts Lawsuit
This article was originally published in The Tan Sheet
FDA's denial of a health claim relating to saw palmetto and benign prostatic hyperplasia violates the First Amendment, the Nutrition Labeling & Education Act (NLEA) and the Administrative Procedures Act (APA), Washington, D.C.-based Emord & Associates asserts in a suit filed Dec. 7.
You may also be interested in...
The Supreme Court should refuse to consider the appropriateness of a proposed saw palmetto/prostatic hyperplasia health claim due to the petitioners' misinterpretation of the FD&C Act, Acting Solicitor General Paul Clemente maintains
FDA's decision to deny a health claim linking saw palmetto extract to the treatment of benign prostatic hypertrophy symptoms was upheld by a Washington, D.C. federal court in a Jan. 3 decision
An issue FDA aims to address at the April 4 public meeting on implementation of the Pearson v. Shalala court decision is how best to convey to consumers that certain dietary supplement health claims do not have as much scientific support as other claims.